Semisynthetic Chemical Modification of the Antifungal Lipopeptide Echinocandin B (ECB): Structure-Activity Studies of the Lipophilic and Geometric Parameters of Polyarylated Acyl Analogs of ECB

Journal of Medicinal Chemistry

Volumn 38, Issue 17, 1995, Pages 3271-3281

  Debono, Manuel ^a   Turner, William W ^a   LaGrandeur, Lisa ^a   Burkhardt, Fred J ^a   Nissen, Jeffrey S ^a   Nichols, Kimberly K ^a   Rodriguez, Michael J ^a   Zweifel, Mark J ^a   Zeckner, Douglas J ^a   Gordee, Robert S ^a   Tang, Julia ^a   Parr, Thomas R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACULEACIN A; AMPHOTERICIN B; ANIDULAFUNGIN; CILOFUNGIN; ECHINOCANDIN B; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; GLUCAN SYNTHASE; ITRACONAZOLE; LINOLEIC ACID; LIPOPEPTIDE;

ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CHEMICAL MODIFICATION; CONTROLLED STUDY; DEACYLATION; DRUG POTENCY; DRUG SYNTHESIS; GEOMETRY; INTRAVENOUS DRUG ADMINISTRATION; LIPOPHILICITY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; ORAL DRUG ADMINISTRATION; STRUCTURE ACTIVITY RELATION;

ACYLATION; ANIMAL; ANTIBIOTICS, ANTIFUNGAL; ANTIBIOTICS, PEPTIDE; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; SPECTRUM ANALYSIS, MASS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029154315     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00017a012     Document Type: Article

References (45)

1. Armstrong, D.; Schmitt, J. J. In Handbook of Experimental Pharmocol. Vol. 96, Springer-Verlag: New York, 1990; pp 439-454.
2. Anaissie, E. Opportunistic Mycoses in the Immunocompromised Host: Experience at the Cancer Center and Review. Clin. Infect. Dis. 1992, 14 (Suppl. 1), S43-S53.
3. Gallis, H. A.; Drew, R. H.; Pickard, W. W. Amphotericin B: 30 Years of Clinical Experience. Rev. Infect. Dis. 1990, 12, 308-329.
4. Saag, M. S.; Dismukes, W. E. Azole Antifungal Agents: Emphasis on New Triazoles. Antimicrob. Agents Chemother. 1988, 32, 1-8.
5. Graybill, J. R. Systemic Azole Antifungal Drugs-Into the 1990’s. In Handbook of Experimental Pharmocol. Vol. 96, Chemotherap. of Fungal Diseases; Ryley, J. F., Ed.; Springer-Verlag: New York, 1990; pp 455-482.
6. Debono, M.; Gordee, R. S. Drug Discovery: Nature’s Approach. In Handbook of Experimental Pharmocol. Vol. 96, Chermotherap. of Fungal Diseases; Ryley, J. F., Ed.; Springer-Verlag: Berlin, 1990; pp 77-109.
7. Gordee, R. S.; Zeckner, D. J.; Ellis, L. F.; Thakkar, A. L.; Howard, L. C. In Vitro and In Vivo Anti-Candida Activity and Toxicology of LY121019. J. Antibiot. 1984, 37, 1054-1065.
8. Yamaguchi, H.; Hiratani, T.; Iwata, K.; Yamamoto, Y. Studies of the Mechanism of Antifungal Action of Aculeacin A. J. Antibiot. 1982, 35, 210-219.
9. Sawistowska-Schroder, E. T.; Kerridge, D.; Perry, H. Echinocandin Inhibition of 1, 3-Beta-D-glucan Synthase from Candida albicans. FEBS Lett. 1984, 173, 134-138.
10. Hector, R. F. Compounds Active Against Cell Walls of Medically Important Fungi. Clin. Microbiol. Rev. 1993, 6, 1-21.
11. Schmatz, D. M.; Romancheck, M. A.; Pittarelli, L. A.; Schwartz, R. E.; Fromtling, R. A.; Nollstadt, K. H.; Vanmiddlesworth, F. L.; Wilson, K. E.; Turner, M. J. Treatment of Pneumocystilis carini Pneumonia with 1, 3-β-Glucan Synthesis Inhibitors. Proc. Natl. Acad. Sci. U. SA. 1990, 87, 5950-5954.
12. Matsumoto, Y.; Matsuda, S.; Tegoshi, T. Yeast Glucan in the Cyst Wall of Pneumocystis carinii. J. Protozool. 1989, 36, 21S-22S.
13. Farkas, V. Biosynthesis of Cell Walls of Fungi. Microbiol. Rev. 1979, 43, 117-144.
14. Farkas, V. Fungal Cell Walls: Their Structure, Biosynthesis and Biotechnological Aspects. Acta Biotechnol. 1990, 10, 225-238.
15. Peberdy, J. F. Fungal Cell Walls - A Review. In Biochemistry of Cell Walls and Membranes In Fungi; Kuhn, A., Trinci, P. J., Jung, M. J., Goosey, M. W., Copping, L. G., Eds.; Springer-Verlag: Berlin/New York, 1990; pp 5-24.
16. Taft, C. S.; Stark, T.; Selitrennikoff, C. P. Cilofungin (LY121019) Inhibits Candida albicans (1-3)-β-D-Glucan Synthase Activity. Antimicrob. Agents Chemother. 1988, 32, 1901-1903.
17. Cassone, A. Cell Wall of Pathogenic Yeasts and Implication for Antimycotic Therapy. Drugs Exp. Clin. Res. 1986, 12, 635-643.
18. Gordee, R. S.; Debono, M.; Parr, T. R., Jr. The Fungal Cell Wall - A Target for Lipopeptide Antifungal Agents. In New Approaches for Antifungal Drugs; Fernandes, P. B., Ed.; Birkhauser: Boston, MA, 1992; pp 46-63.
19. Debono, M.; Gordee, R. S. Antibiotics That Inhibit Fungal Cell Wall Development. Annu. Rev. Microbiol. 1994, 48, 471-497.
20. Debono, M.; Gordee, R. S. Antibiotics That Inhibit Fungal Cell Wall Development. Annu. Rev. Microbiol. 1994, 48, 471-497.
21. Balkovec, J. M. Lipopeptide Antifungal Agents. Expert Opin. Invest. Drugs 1994, 3, 65-82.
22. Debono, M.; Abbott, B. J.; Turner, J. R.; Howard, L. C.; Gordee, R. S.; Hunt, A. S.; Barnhart, M.; Molloy, R. M.; Willard, K. E.; Fukuda, D. S.; Butler, T. F.; Zeckner, D. J. Synthesis and Evaluation of LY121019, a Member of a Series of Semi-synthetic Analogues of the Antifungal Lipopeptide Echinocandin B. Ann. N. Y. Acad. Sci. 1988, 544, 152-167.
23. Benz, F.; Knusel, F.; Nuesch, J.; Treichler, H.; Voser, W.; Nyfeler, R.; Keller-Schlierlein, W. Echinocandin B. Ein Neuartiges Polypetide-antibiotikum aus Aspergillus nidulans var Echinulatus: Isolierung und Bausteine. (Metabolie products of microorganisms. 143.
24. Echinocandin B, a new polypeptide antibiotic from Aspergillus nidulans var echinulatus. Isolation and components. Helv. Chim. Acta 1974, 57, 2459-2477.
25. Roy, K.; Mukhopadhyay, T.; Reddy, G. C. S.; Desikan, K. R.; Ganguli, B. N. Mulundocandin, a New Lipopeptide Antibiotic. I. Taxonomy, Fermentation, Isolation and Characterization. J. Antibiot. 1987, 40, 275-280.
26. Schwartz, R. E.; Giacobbe, R. A.; Bland, J. A.; Monaghan, R. L. 1-671, 329, a New Antifungal Agent. I. Fermentation and Isolation. J. Antibiot. 1989, 42, 163-167.
27. Tscherter, H.; Dreyfuss, M. M. Belgian patent 889, 955, 1982.
28. Balkovec, J. M.; Black, R. M.; Hammond, M. L.; Heck, J. V.; Zambias, R. A.; Abruzzo, G.; Bartizal, K.; Kropp, H.; Trainor, C.; Schwartz, R. E.; McFadden, D. C.; Nollstadt, K. H.; Pittarelli, L. A.; Powles, M. A.; Schmatz, D. M. Synthesis, Stability, and Biological Evaluation of Water-soluble Prodrugs of a New Echinocandin Lipopeptide. Discovery of a Potential Clinical Agent for the Treatment of Systemic Candidiasis and Pneumocystis Carinii Pneumonia (PCP). J. Med. Chem. 1992, 35, 194-198.
29. Iwamoto, T.; Fujie, A.; Sakamoto, K.; Tsurumi, Y.; Shigematsu, N.; Yamashita, M.; Hashimoto, S.; Okuhara, M.; Kohsaka, M. WF11899A, B, and C, Novel Antifungal Lipopeptides I. Taxonomy, Fermentation, Isolation and Physico-Chemical Properties. J. Antibiot. 1994, 47, 1084-1091.
30. Hammond, M. L. Chemical and Structure-Activity Studies of the Echinocandin Lipopeptides. In Cutaneous Antifungal Agents; Rippon, J. W., Fromtling, R. A., Eds.; Marcel Dekker: New York, 1993; pp 395-420.
31. Current, W. L.; Boylan, C. J. Anti-pneumocysitis Activity of Antifungal Compounds Cilofungin and Echinocandin B. Presented at the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 1990; Abstract 207.
32. Denning, D. W.; Stevens, D. A. Efficacy of Cilofungin Alone and in Combination with Amphotericin B in a Murine Model of Disseminated Aspergillosis. Antimicrob. Agents Chemother. 1991, 35, 1329-1333.
33. Taft, C. S.; Selitrennikoff, C. P. Cilofungin Inhibition of (1, 3)-β-Glucan Synthase: The Lipophilic Side Chain is Essential for Inhibition of Enzyme Activity. J. Antibiot. 1990, 43, 433-437.
34. Boeck, L. D.; Fukuda, D. S.; Abbott, B. J.; Debono, M. Deacylation of Echinocandin B by Actinoplanes utahensis. J. Antibiot. 1989, 42, 382-388.
35. Debono, M.; Abbott, B. J.; Fukuda, D. S.; Barnhart, M.; Willard, K. E.; Molloy, R. M.; Michel, K. H.; Turner, J. R.; Butler, T. F.; Hunt, A. H. Synthesis of New Analogs of Echinocandin B by Enzymatic Deacylation and Chemical Reacylation of the Echinocandin B Peptide: Synthesis of the Antifungal Agent Cilogungin (LY121019). J. Antibiot. 1989, 42, 389-397.
36. Manhas, M. S.; Hoffman, W. H.; Lai, B.; Bose, A. K. Steroids. Part X. A Convenient Synthesis of Alkyl Aryl Ethers. J. Chem. Soc., Perkin Trans. 1 1975, 461-463.
37. Suzuki, A.; Miyaura, N.; Yanagi, T. The Palladium-catalyzed Cross-Coupling Reaction of Phenylboronic Acid with Haloarenes in the Presence of Bases. Synth. Commun. 1981, 11, 513-519.
38. Heck, R. F. Palladium Reagents in Organic Syntheses; Academic Press: San Diego, CA, 1990; pp 299-306.
39. Drahowzal, F. A. Alkylation of Aromatics with Haloalkanes. In Friedel-Crafts and Related Reactions Vol. 2 Part 1; Olah, G. A., Ed.; John Wiley & Sons Publishers: New York, 1964; pp 417-475.
40. Tang, J.; Parr, T. R., Jr. W-1 Solubilization and Kinetics of Inhibition by Cilofungin of Candida albicans (1, 3)-β-D-Glucan Synthase. Antimicrob. Agents Chemother. 1991, 35, 99-103.
41. Hansch, C.; Bjorkroth, J. P.; Leo, A. Hydrophobicity and Central Nervous System Agents: on the Principle of Minimal Hydrophobicity in Drug Design. J. Pharm. Sci. 1987, 79, 663-687.
42. Pomona College Medchem Software Manual, Version 3; 1984.
43. Boyd, D. B. Unpublished work, Lilly Research Laboratories, 1984-1986.
44. Rekker, R. F.; de Kort, H. M. The Hydrophobie Fragmental Constant: an Extension to a 1000 Data Point Set. Eur. J. Med. Chem. 1979, 14, 479-488.
45. Reed, F. J.; Muench, H. A Simple Method for Estimating 50 per cent Endpoints. Am. J. Hyg. 1938, 27, 493-497.